CORDIS
EU research results

CORDIS

English EN
Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

Objective

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular disease (CVD), diabetes (DM), sarcopenia and cancer, which account for >25% of the global disease burden. The CaSR is a unique GPCR whose principal physiological ligand is the Ca2+ ion; it is expressed almost ubiquitously; interacts with multiple Gα subtypes regulating highly divergent downstream signalling pathways, depending on the cellular context. The CaSR Biomedicine is a fully translational project that utilises the concept of a single molecule, the CaSR, influencing a range of physiological and disease processes, to develop a unique, strong multidisciplinary and intersectoral scientific training programme preparing 14 young scientists to become specialists in GPCR biology and signalling.
The objectives of CaSR Biomedicine are:
1. Educate and train Early Stage Researchers to become highly innovative scientists to enhance their career perspective.
2. Elucidate ligand- and tissue-dependent differences in CaSR physiology by examining its functions at cellular level and thus to contribute to the understanding of GPCR signalling in general;
3. Assess how CaSR function is altered in AD, CVD, DM, sarcopenia, and cancer, and to find innovative CaSR-based therapeutic approaches for these major, age-related disorders.
4. Establish long-lasting interdisciplinary and intersectoral cooperation among researchers and between researchers and industry, to strengthen the European Research Area.
Therefore the CaSR Biomedicine will investigate the complexity of CaSR signalling and function to identify CaSR-based therapeutic approaches to diseases linked to changes in CaSR expression or function (AD, CVD, DM, sarcopenia, and cancer).

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN

Address

Spitalgasse 23
1090 Wien

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 511 868,16

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 273 287,88

FUNDACIO SANT JOAN DE DEU

Spain

EU Contribution

€ 247 872,96

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 290 081,88

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 273 287,88

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 258 061,32

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITE DE PICARDIE JULES VERNE

France

EU Contribution

€ 262 875,60

STICHTING VU

Netherlands

EU Contribution

€ 255 374,28

BIOTALENTUM TUDASFEJLESZTO KFT

Hungary

EU Contribution

€ 223 913,52

S.A.F.AN. BIOINFORMATICS - SAS DI PUGLIESE LUISA

Italy

EU Contribution

€ 258 061,32

TISSUEGNOSTICS GMBH

Austria

EU Contribution

€ 255 934,08

Partners (5)

Sort alphabetically

Expand all

FH JOANNEUM GESELLSCHAFT MBH

AHT-Management

NOVARTIS PHARMA AG

Amgen GmbH

IMABIOTECH SAS

Project information

Grant agreement ID: 675228

Status

Ongoing project

  • Start date

    1 March 2016

  • End date

    29 February 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 657 194,64

  • EU contribution

    € 3 657 194,64

Coordinated by:

MEDIZINISCHE UNIVERSITAET WIEN

Austria